Abgenix and Elan in XenoMouse pact
Abgenix has signed a research license and option agreement with Elansubsidiary Neuralab, giving the latter access to use Abgenix' XenoMouse technology to generate fully-human monoclonal antibodies to an undisclosed antigen in the field of neurological disease. Elan will be responsible for development, manufacturing, and marketing of any products that arise from the collaboration, but no financial details were disclosed.
Elan is Abgenix' 16th XenoMouse partner, and the firm has also signed deals (since October last year) with CuraGen, Chiron, Human Genome Sciences, Pfizer and the US Army. Scott Greer, chief executive of Abgenix, noted that interest among pharmaceutical and biotechnology companies for the company's technology "to make fully-human antibodies for drug development continues to grow."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze